Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Financing Activities (2016 - 2025)

Assembly Biosciences has reported Cash from Financing Activities over the past 11 years, most recently at $456000.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $456000.0 for Q4 2025, down 97.32% from a year ago — trailing twelve months through Dec 2025 was $174.7 million (up 493.12% YoY), and the annual figure for FY2025 was $174.7 million, up 493.12%.
  • Cash from Financing Activities for Q4 2025 was $456000.0 at Assembly Biosciences, down from $171.9 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ASMB hit a ceiling of $171.9 million in Q3 2025 and a floor of $134000.0 in Q2 2023.
  • Median Cash from Financing Activities over the past 5 years was $4.5 million (2023), compared with a mean of $18.1 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 28586.55% in 2021 and later tumbled 97.32% in 2025.
  • Assembly Biosciences' Cash from Financing Activities stood at $2.7 million in 2021, then tumbled by 83.89% to $437000.0 in 2022, then surged by 2003.43% to $9.2 million in 2023, then surged by 84.89% to $17.0 million in 2024, then tumbled by 97.32% to $456000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $456000.0 (Q4 2025), $171.9 million (Q3 2025), and $357000.0 (Q2 2025) per Business Quant data.